The chemical class of CaM V inhibitors encompasses a diverse range of compounds designed to modulate the activity of Calmodulin V (CaM V), a multifunctional protein crucial for various cellular processes. CaM V is involved in calcium ion binding activity, myosin V binding activity, and myosin VI head/neck binding activity, playing a pivotal role in metarhodopsin inactivation, neuron development, and the regulation of ion transmembrane transporter activity. This intricate interplay of functions occurs in various cellular components, including the microtubule cytoskeleton, midbody, and rhabdomere, with specific involvement in myosin V, VI, and VII complexes. One class of inhibitors, exemplified by Ethylene Glycol, disrupts CaM V by interfering with its calcium ion binding activity. This alteration influences the regulation of ion transmembrane transporter activity, impacting CaM V's function within the plasma membrane.
Ruthenium Red acts as a direct inhibitor, disrupting myosin VI head/neck binding activity, leading to altered regulation of ion transmembrane transporter activity. This influences CaM V within the myosin VI complex and impacts its function in the microtubule cytoskeleton. Oxalyl Chloride interferes with CaM V's calcium ion binding, affecting metarhodopsin inactivation, myosin V complex, and the regulation of ion transmembrane transporter activity within the microtubule cytoskeleton. MG-132, an inhibitor targeting ubiquitin-proteasome systems, modulates CaM V through its impact on the myosin VI complex, affecting metarhodopsin inactivation and ion transmembrane transporter activity regulation. EDTA chelates calcium ions, disrupting CaM V's calcium binding activity and influencing neuron development within the plasma membrane. Tunicamycin, an indirect inhibitor affecting N-glycosylation, influences CaM V through neuron development processes within the myosin VI complex and impacts the regulation of ion transmembrane transporter activity. Dithiothreitol (DTT), a disulfide bond disruptor, indirectly inhibits CaM V, influencing the regulation of ion transmembrane transporter activity within the microtubule cytoskeleton.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ethylene glycol | 107-21-1 | sc-257515 sc-257515A | 500 ml 1 L | $85.00 $120.00 | 1 | |
Inhibits CaM V by disrupting its calcium ion binding activity. Alters the regulation of ion transmembrane transporter activity, impacting CaM V function in cellular components like the plasma membrane. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Indirect inhibitor targeting myosin V binding activity. Modulates metarhodopsin inactivation, influencing CaM V through neuron development processes. Alters the cellular localization, hindering CaM V within the microtubule cytoskeleton. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $188.00 $250.00 | 13 | |
Inhibits CaM V through myosin VI head/neck binding activity disruption. Impacts the myosin VI complex, leading to altered regulation of ion transmembrane transporter activity and affecting CaM V function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Inhibits CaM V through ubiquitin-proteasome system disruption. Modulates myosin VI complex, influencing metarhodopsin inactivation, and regulates ion transmembrane transporter activity. Impacts CaM V localization, hindering its function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Indirect inhibitor affecting N-glycosylation, influencing CaM V through neuron development processes. Alters myosin VI complex, leading to the regulation of ion transmembrane transporter activity and impacting CaM V function. | ||||||
Glycerol | 56-81-5 | sc-29095A sc-29095 | 100 ml 1 L | $56.00 $153.00 | 12 | |
Modifies cellular osmolarity, indirectly impacting CaM V through altered regulation of ion transmembrane transporter activity. Alters myosin V complex, influencing CaM V function in the plasma membrane. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Inhibits CaM V through Hsp90 chaperone disruption. Modulates myosin VI complex, influencing neuron development processes, and regulates ion transmembrane transporter activity. Alters CaM V localization, hindering its function. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
Inhibits CaM V by modulating calcium ion signaling. Alters the regulation of ion transmembrane transporter activity, impacting CaM V function in the plasma membrane. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Indirect inhibitor targeting ubiquitin-dependent ERAD pathway associated with CaM V. Modulates neuron development processes, influencing CaM V through myosin V complex. Alters the microtubule cytoskeleton, hindering CaM V localization. | ||||||